| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| ETOP ADOPT | 23-23 | Stage IIB-IIIB (N2) resectable NSCLC |
The purpose of this study is to evaluate the efficacy and safety of adding adjuvant durvalumab after neoadjuvant chemo plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC |
DSSG Group: Lung
KRYSTAL-4 (CA239-0004 )
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| KRYSTAL-4 (CA239-0004 ) | 25-22 | Non-squamous Non-small Cell Lung Cancer |
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation |
MK-2870-023
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MK-2870-023 | 24-107 | Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) |
This study is to see if survival and progression-free survival are better for patients on Pemrolizumab on its own or in combination with Sacituzumab Tirumotecan. Patients will be on the study maintenance treatment for just under 2 years, as long as their cancer is not getting worse or they do not have serious side effects. About 851 people will be in the study in total. |
TACTI-004
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| TACTI-004 | 24-20 | With Advanced/Metastatic Non Small Cell Lung Cancer |
The purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy among adults with metastatic non-small cell lung cancer (NSCLC). |
22-23 NeoCOAST-2
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| 22-23 NeoCOAST-2 | 22-23 | Early-Stage (II to IIIA) Non-small Cell Lung Cancer |
The purpose is to evaluate pathologic complete response in patients treated with Durvalumab with Oleclumab or Monalizumab. Also safety and tolerability of Durvalumab. |
Krystal-7
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Krystal-7 | 22-07 | Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation |
This Phase 2 study will evaluate the efficacy and safety of MRTX849 on its own and in combination with pembrolizumab. The Phase 3 portion of the study compares the efficacy of Adagrasib in combination with pembrolizumab versus pembrolizumab plus chemotherapy |
SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours | 18-33 | inoperable, early stage, high-risk ultracentrally located lung tumours. |
The purpose of the study is to determine the safety of the radiation therapy treatment regimen in terms of side effects experienced within one year after treatment which are related to the radiation therapy. |